REVVITY CELLULAR TECHNOLOGIES GMBH – Trademark Portfolio

Entity Type: 27

REVVITY CELLULAR TECHNOLOGIES GMBH holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 8 filings in this category. Currently, 6 trademarks are registered and 2 are pending. Notable registered marks include NIVO, HARMONY, ACAPELLA, OPERETTA, and CELLCARRIER. The owner is based in HAMBURG.

SCHNACKENBURGALLEE 114

HAMBURG 22525 , DE

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

REVVITY CELLULAR TECHNOLOGIES GMBH's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

9
Computers & Electronics (8 filings)

Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments

Frequently Asked Questions

How many trademarks does REVVITY CELLULAR TECHNOLOGIES GMBH have?

REVVITY CELLULAR TECHNOLOGIES GMBH has 8 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 pending.

What trademark classes does REVVITY CELLULAR TECHNOLOGIES GMBH file in?

REVVITY CELLULAR TECHNOLOGIES GMBH files trademarks across 1 Nice Classification class. The most active classes are Class 9 (Computers & Electronics). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.

What are REVVITY CELLULAR TECHNOLOGIES GMBH's most well-known trademarks?

REVVITY CELLULAR TECHNOLOGIES GMBH's registered trademark portfolio includes well-known marks such as NIVO, HARMONY, ACAPELLA, OPERETTA, and CELLCARRIER. These are among 6 currently registered trademarks in the portfolio.

What is REVVITY CELLULAR TECHNOLOGIES GMBH's trademark registration success rate?

REVVITY CELLULAR TECHNOLOGIES GMBH has a 100% trademark registration rate, with 6 out of 6 resolved applications resulting in successful registration. Currently, 2 applications are pending review.